Understanding the Role of the Gut Microbiome in NAFLD
Posted 30th August 2019 by Liv Sewell
NAFLD is the primary contributor to chronic liver disease worldwide with incident rates of 20-30% in western countries and 5-18% in Asia. The discovery of early stage biomarkers for patients with the reversible form of the disease is therefore a research priority. Recent work has shown perturbation of the microbiome and specific microbiome-associated metabolites contribute to the phenotype of NAFLD.
Lesley Hoyles is Associate Professor in Microbiology at Nottingham Trent University, UK. She combines microbiology and computational biology/bioinformatics approaches in vitro and in vivo to understand how members of the gut microbiota function and influence human health and disease.
In this presentation, given at the 6th Microbiome R&D and Business Collaboration Forum: Europe, Lesley presents findings from recent integrated systems biology studies examining the role of the microbiome in NAFLD, including the EU FLORINASH study, which aimed to discover previously unidentified metabolic markers for the diagnosis and prediction of patient risk.
Leave a Reply